Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi

suck pdf from helios

10.1016/j.mehy.2020.109777

http://scihub22266oqcxt.onion/10.1016/j.mehy.2020.109777
suck pdf from google scholar
32344314!7194824!32344314
unlimited free pdf from europmc32344314    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32344314  :  Publisher
PDF vom PMID32344314

suck abstract from ncbi

pmid32344314
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents #MMPMID32344314
  • Yaqinuddin A; Kashir J
  • Med Hypotheses 2020[Apr]; 140 (ä): 109777 PMID32344314show ga
  • Following the outbreak of a novel coronavirus (SARS-CoV-2), studies suggest that the resultant disease (COVID-19) is more severe in individuals with a weakened immune system. Cytotoxic T-cells (CTLs) and Natural Killer (NK) cells are required to generate an effective immune response against viruses, functional exhaustion of which enables disease progression. Patients with severe COVID-19 present significantly lower lymphocyte, and higher neutrophil, counts in blood. Specifically, CD8(+) lymphocytes and NK cells were significantly reduced in cases of severe infection compared to patients with mild infection and healthy individuals. The NK group 2 member A (NKG2A) receptor transduces inhibitory signalling, suppressing NK cytokine secretion and cytotoxicity. Overexpression of NKG2A has been observed on CD8(+) and NK cells of COVID-19 infected patients compared to healthy controls, while NKG2A overexpression also functionally exhausts CD8(+) cells and NK cells, resulting in a severely compromised innate immune response. Blocking NKG2A on CD8(+) cells and NK cells in cancers modulated tumor growth, restoring CD8(+) T and NK cell function. A recently proposed mechanism via which SARS-CoV-2 overrides innate immune response of the host is by over-expressing NKG2A on CD(+) T and NK cells, culminating in functional exhaustion of the immune response against the viral pathogen. Monalizumab is an inhibiting antibody against NKG2A which can restore the function of CD8 + T and NK cells in cancers, successfully ceasing tumor progression with no significant side effects in Phase 2 clinical trials. We hypothesize that patients with severe COVID-19 have a severely compromised innate immune response and could be treated via the use of Monalizumab, interferon alpha, chloroquine, and other antiviral agents.
  • ä


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    109777 ä.140 2020